Lifecore Biomedical, Inc. LFCR 深 沪
已收盘 02-06 16:00:00 美东时间
7.57
+0.010
+0.13%
华盛通- 最 高7.91
- 今 开7.67
- 成交量 13.92万股
- 最 低 7.435
- 昨 收 7.56
- 总市值 2.84亿
- 52周最高 8.9799
- 市盈率 静 --
- 换手率 0.37%
- 52周最低 4.76
- 委 比 -43.97%
- 总股本 3746.64万
- 历史最高 15.96
- 量 比 0.75
- 振 幅 6.28%
- 历史最低 1.52
- 每 手 1
- 风险率 0.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lifecore Biomedical (LFCR) Receives a Buy from Craig-Hallum
In a report released on January 29, Matt Hewitt from Craig-Hallum maintained a ...
02-02 00:25
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Lifecore Biomedical announced on January 14, 2026, that its compensation committee approved RSU awards and stock options to two newly hired employees under the Equity Inducement Plan. The RSUs were granted for 1,738 shares, vesting over three years, and stock options for 8,775 shares, vesting monthly with a seven-year term. Both awards were granted as inducement equity awards under Nasdaq Listing Rule 5635(c)(4) and are governed by the Inducement...
01-16 21:45
Lifecore Biomedical Lands Major Global Pharma Deal to Make Injectable Drug in the US
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has signed a CDMO master services agreement with a new large
2025-12-17 20:09
Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer
Lifecore Biomedical has signed a CDMO master services agreement with a global pharmaceutical customer. The agreement involves development services and tech transfer for an injectable product, with plans to transfer commercial supply to Lifecore's facilities. This is the second agreement with a multinational pharma company in three months. Based on current revenue, the new partner has potential to become one of Lifecore's top five commercial custo...
2025-12-17 12:00
Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference
Lifecore Biomedical, Inc. (NASDAQ: LFCR) will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, California. The company’s CEO, Paul Josephs, and CFO, Ryan Lake, will attend 1-on-1 meetings. Lifecore, a leading CDMO specializing in sterile injectable pharmaceuticals and hyaluronic acid manufacturing, has over 40 years of experience. For more information, visit www.lifecore.com.
2025-12-16 12:00
Lifecore Biomedical to Participate in Upcoming Investor Conferences
Lifecore Biomedical, Inc. (NASDAQ: LFCR) announced its participation in two upcoming investor conferences. The company’s CEO, Paul Josephs, will deliver a presentation at the Jefferies 2025 Global Healthcare Conference in London on November 18, 2025. Additionally, Josephs will participate in a fireside chat at the Stephens Annual Investment Conference in Nashville on November 20, 2025. Both events will include webcasts accessible via Lifecore’s i...
2025-11-11 21:05
Greenhaven Road Capital Main Fund exits IWGFF, ALTG, SOC
The Greenhaven Road Capital Main Fund has underperformed with a return of -9% during Q3 2025. During the third quarter, the fund exited International Workplace (OTCPK:IWGFF), Alta Equipment Group (NYS...
2025-11-11 00:46
Lifecore Expands CDMO Business, Becomes Supplier Of Choice For Leading Injectable Drug
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has signed an agreement with a leading global pharmaceutical
2025-10-29 19:23
Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company
Lifecore Biomedical has signed two agreements: one to transfer commercial manufacturing of a leading injectable pharmaceutical product from a global pharmaceutical company, making it the new supplier, and another with an early-stage biotech company for pre-clinical formulation development. These signings highlight Lifecore's growing reputation and support its growth strategies, including expanding CDMO business and domestic manufacturing capacity...
2025-10-29 11:00
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market
Lifecore Biomedical and PolyPeptide Laboratories have signed a collaboration agreement to offer integrated, end-to-end solutions for peptide-based pharmaceutical customers in the U.S. The partnership combines PolyPeptide's peptide manufacturing expertise with Lifecore's formulation, fill/finish, and packaging capabilities, aiming to accelerate development timelines, reduce costs, and ensure a reliable U.S.-based supply chain. The collaboration wi...
2025-10-28 11:00
